Page URL:

Direct-to-consumer genetic test results are questionable, research suggests

6 June 2011
Appeared in BioNews 610

Direct-to-consumer (DTC) genetic tests provide an inaccurate prediction of disease risk and offer little benefit to consumers, scientists claim.

Researchers from the Erasmus University Medical Centre in the Netherlands and Harvard Medical School, USA examined two currently-available tests and found results varied widely depending on the calculation methods used.

Professor Cecile Janssens and team examined the risk predictions supplied by two DTC companies, deCODEme and 23andMe. The researchers simulated genotype data for 100,000 individuals based on established genotype frequencies and using formulas and risk data provided by the companies, and obtained predicted risks for eight common multi-factorial diseases.

Some tests using deCODEme and 23andMe risk models calculated risks higher than 100 percent for five out of eight diseases. 'This in itself should be enough to raise considerable concern about the accuracy of these predictions - a risk can never be higher than 100 percent', researcher Rachel Kalf explains. Predicted risks higher than 50 percent were frequently observed for one company, but were less common in company two.

For Age-Related Macular Degeneration (AMD), the disease with the highest predictive ability, both companies assumed the population risk to be around eight percent. Of all subjects designated as having an increased risk, 16 percent from 23andMe and 19 percent from deCODEme's, would develop AMD, compared to the four percent found in the rest of the population studied. 'So individuals in the increased risk group may have a four-fold increased risk of disease, but they are still far more likely not to develop the disease at all', said Professor Janssens.

Furthermore, the tests studied genetic factors only, however many diseases are influenced by lifestyle and environmental factors. 'For complex diseases, if you ignore these non-genetic factors, you are looking at only a small part of the picture and missing the main story', Professor Janssens added.

This has triggered calls for tighter regulations surrounding DTC genetic testing, with critics saying the tests are a waste of money while also potentially misguiding people with regards to future health problems.

However, Kari Stefánsson, chief executive of deCODEme, queried the research findings saying: 'We never report a lifetime risk over 90 percent. This is not how we use these models'.

The research was presented at the European Human Genetics Conference in Amsterdam, May 2011.

Genetics tests flawed and inaccurate, say Dutch scientists
Guardian |  30 May 2011
Risk predictions from direct-to-consumer personal genome testing: What do consumers really learn about common disease risk?
European Human Genetics Conference 2011 |  28 May 2011
7 October 2013 - by Dr Sophie Pryor 
A US genetics company has been awarded a patent that relates to a DNA analysis service that predicts a baby's traits on the basis of its parents' genes....
9 July 2012 - by Ruth Saunders 
Two novel gene variants linked to breast size may also also influence the risk of breast cancer, according to a study carried out by US genetics company 23andMe....
6 June 2012 - by Ruth Saunders 
23andMe, a personal genomics company, announced last week that it had been successfully awarded a patent for a gene variant which appears to protect against a high-risk mutation for Parkinson's disease...
2 April 2012 - by Ruth Saunders 
Last week the Parliamentary Office of Science and Technology (POST) released a POST Note - a guide for MPs and other parliamentarians on science and technology issues - on consumer genetic testing...
3 October 2011 - by Dr Vivienne Raper and Ruth Saunders 
'We are not our genomes'. Lone Frank, the author of 'My Beautiful Genome – Exposing our Genetic Quirks, One Genome at a Time' spoke to BioNews about her latest book, the recent surge in direct-to-consumer genetic tests, the ethical dilemmas they could pose and what we can understand from such tests. As he says, 'genetics is a work in progress'...
18 October 2010 - by MacKenna Roberts 
The UK's Nuffield Council on Bioethics has reported that direct-to-consumer personal genetic profiling services used to predict people's genetic susceptibility for common diseases, such as Parkinson's and diabetes, are often inconclusive, misleading and can potentially cause unnecessary anxiety, complacency or distress when no treatment is available...
27 August 2010 - by Dr Stuart Hogarth and Professor David Melzer 
Earlier this month the UK's Human Genetics Commission (HGC) published a new document entitled 'A Common Framework of Principles for Direct-to-Consumer Genetic Testing Services' in a bid to define standards for this emergent sector...
9 August 2010 - by Chris Chatterton 
The Human Genome Commission (HGC) has published a new ‘Common Framework of Principles’ for direct-to-consumer (DTC) genetic tests on 4 August....
26 July 2010 - by Chris Chatterton 
Direct-to-consumer genetic tests were called into question by the US authorities last week. An undercover investigation by the US Government Accountability Office (GAO) found that test results were often inaccurate and misleading....
28 June 2010 - by Seil Collins 
The Food and Drug Administration (FDA) has told five US companies that the genetic tests they sell directly to consumers are unapproved....
to add a Comment.

By posting a comment you agree to abide by the BioNews terms and conditions

Syndicate this story - click here to enquire about using this story.